JP2021525275A - ２，２，２−トリフルオロ酢酸１−（２，４−ジメチルフェニル）−２−［（３−メトキシフェニル）メチレン］ ヒドラジド多形体およびその製造方法 - Google Patents

２，２，２−トリフルオロ酢酸１−（２，４−ジメチルフェニル）−２−［（３−メトキシフェニル）メチレン］ ヒドラジド多形体およびその製造方法 Download PDF

Info

Publication number
JP2021525275A
JP2021525275A JP2020567741A JP2020567741A JP2021525275A JP 2021525275 A JP2021525275 A JP 2021525275A JP 2020567741 A JP2020567741 A JP 2020567741A JP 2020567741 A JP2020567741 A JP 2020567741A JP 2021525275 A JP2021525275 A JP 2021525275A
Authority
JP
Japan
Prior art keywords
solvent
hydrazide
methoxyphenyl
methylene
trifluoroacetic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020567741A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525275A5 (https=
Inventor
オニール，マイケル
キドン，バーバラ
ジャンズ，ビル
ウー，ホンチアオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janz Bill
Kidon Barbara
Original Assignee
Janz Bill
Kidon Barbara
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janz Bill, Kidon Barbara filed Critical Janz Bill
Publication of JP2021525275A publication Critical patent/JP2021525275A/ja
Publication of JP2021525275A5 publication Critical patent/JP2021525275A5/ja
Priority to JP2023218036A priority Critical patent/JP2024038090A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/16—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of hydrazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020567741A 2018-02-21 2019-02-20 ２，２，２−トリフルオロ酢酸１−（２，４−ジメチルフェニル）−２−［（３−メトキシフェニル）メチレン］ ヒドラジド多形体およびその製造方法 Pending JP2021525275A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023218036A JP2024038090A (ja) 2018-02-21 2023-12-25 ２，２，２－トリフルオロ酢酸１－（２，４－ジメチルフェニル）－２－［（３－メトキシフェニル）メチレン］ ヒドラジド多形体およびその製造方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862633441P 2018-02-21 2018-02-21
US62/633,441 2018-02-21
PCT/US2019/018835 WO2019164997A1 (en) 2018-02-21 2019-02-20 2,2,2-trifluoroacetic acid 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl) methylene] hydrazide polymorphs and method of making the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023218036A Division JP2024038090A (ja) 2018-02-21 2023-12-25 ２，２，２－トリフルオロ酢酸１－（２，４－ジメチルフェニル）－２－［（３－メトキシフェニル）メチレン］ ヒドラジド多形体およびその製造方法

Publications (2)

Publication Number Publication Date
JP2021525275A true JP2021525275A (ja) 2021-09-24
JP2021525275A5 JP2021525275A5 (https=) 2022-03-02

Family

ID=67686904

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020567741A Pending JP2021525275A (ja) 2018-02-21 2019-02-20 ２，２，２−トリフルオロ酢酸１−（２，４−ジメチルフェニル）−２−［（３−メトキシフェニル）メチレン］ ヒドラジド多形体およびその製造方法
JP2023218036A Pending JP2024038090A (ja) 2018-02-21 2023-12-25 ２，２，２－トリフルオロ酢酸１－（２，４－ジメチルフェニル）－２－［（３－メトキシフェニル）メチレン］ ヒドラジド多形体およびその製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023218036A Pending JP2024038090A (ja) 2018-02-21 2023-12-25 ２，２，２－トリフルオロ酢酸１－（２，４－ジメチルフェニル）－２－［（３－メトキシフェニル）メチレン］ ヒドラジド多形体およびその製造方法

Country Status (6)

Country Link
US (2) US10968167B2 (https=)
EP (1) EP3755316A4 (https=)
JP (2) JP2021525275A (https=)
CN (1) CN113747892A (https=)
CA (1) CA3091782A1 (https=)
WO (1) WO2019164997A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021525275A (ja) * 2018-02-21 2021-09-24 オニール, マイケルO’NEIL, Michael ２，２，２−トリフルオロ酢酸１−（２，４−ジメチルフェニル）−２−［（３−メトキシフェニル）メチレン］ ヒドラジド多形体およびその製造方法
WO2021222438A1 (en) * 2020-04-28 2021-11-04 Abrexa Pharmaceuticals, Inc. Compounds for prevention and treatment of post-intensive care cognitive dysfunction and cognitive dysfunction resulting from respiratory distress

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8779002B2 (en) 2007-10-15 2014-07-15 Salk Institute For Biological Studies Methods for treating a variety of diseases and conditions, and compounds useful therefor
CN105801496B (zh) * 2014-12-31 2018-03-13 广州喜鹊医药有限公司 三氟乙酰肼类化合物及其制备方法和在制药中的应用
WO2017015660A1 (en) * 2015-07-23 2017-01-26 Salk Institute For Biological Studies Prevention and treatment of aging and neurodegenerative diseases
JP2021525275A (ja) * 2018-02-21 2021-09-24 オニール, マイケルO’NEIL, Michael ２，２，２−トリフルオロ酢酸１−（２，４−ジメチルフェニル）−２−［（３−メトキシフェニル）メチレン］ ヒドラジド多形体およびその製造方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALZHEIMER'S RESEARCH & THERAPY, vol. 5(25), JPN6023005033, 2013, pages 1 - 19, ISSN: 0005134995 *
PLOS ONE, vol. 6(12), JPN6023005032, 2011, pages 1 - 17, ISSN: 0005134996 *
実験化学講座（続）２ 分離と精製, JPN6009058003, 25 January 1967 (1967-01-25), pages 159 - 162, ISSN: 0005134998 *
平山令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0005134997 *

Also Published As

Publication number Publication date
EP3755316A1 (en) 2020-12-30
CN113747892A (zh) 2021-12-03
CA3091782A1 (en) 2019-08-29
US11584711B2 (en) 2023-02-21
US20210139416A1 (en) 2021-05-13
WO2019164997A1 (en) 2019-08-29
US10968167B2 (en) 2021-04-06
JP2024038090A (ja) 2024-03-19
US20200399205A1 (en) 2020-12-24
EP3755316A4 (en) 2022-05-25

Similar Documents

Publication Publication Date Title
Pan et al. Solution-mediated polymorphic transformation of CL-20: An approach to prepare purified form ε particles
Láng et al. Polymorph screening of an active material
EA022756B1 (ru) Кристаллические формы элтромбопага и их применение
JP2024038090A (ja) ２，２，２－トリフルオロ酢酸１－（２，４－ジメチルフェニル）－２－［（３－メトキシフェニル）メチレン］ ヒドラジド多形体およびその製造方法
Ma et al. Identification of novel adefovir dipivoxil-saccharin cocrystal polymorphs and their thermodynamic polymorphic transformations
WO2021000687A1 (zh) Pac-1晶型的制备方法
Tandon et al. Art of synthesis of desired polymorphs: A review
Ueda et al. Baloxavir Marboxil shows anomalous conversion of crystal forms from stable to metastable through formation of specific solvate form
KR20140108222A (ko) 결정질 형태의 신속한 식별 및 제조를 위한 방법
Nugrahani et al. Theophylline-Na-sacharrine single crystal isolation for its structure determination
CN114105969A (zh) Btrx-335140的晶型及其制备方法
US11434204B2 (en) Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide
TW201932453A (zh) 法索西坦(fasoracetam)之固體型態
HK40065391A (en) 2,2,2-trifluoroacetic acid 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl) methylene] hydrazide polymorphs and method of making the same
WO2025180349A1 (zh) 化合物的固体及其制备方法和用途
CN116120380B (zh) 葡萄糖胺衍生物的晶型、制备方法及用途
BR112021010975A2 (pt) Formas cristalinas de 1-[(3r,4s)-4-cianotetrahidropiran-3-il]-3-[(2-fluoro-6-metóxi-4-piridil)amino]pirazol-4-carboxamida
JP2015500311A (ja) （１ｒ，４ｒ）−６’−フルオロ−（Ｎ，Ｎ−ジメチル）−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ−［シクロヘキサン−１，１’−ピラノ−［３，４，ｂ］インドール］−４−アミンおよび硫酸の固体形態
CN108503558A (zh) 柳胺酚晶型i、其制备方法及其应用
TW202543648A (zh) 包含布魯頓氏酪胺酸激酶降解劑之固體形式及其用途
CN109415325B (zh) 制备3-[5-氨基-4-(3-氰基苯甲酰基)-吡唑-1-基]-n-环丙基-4-甲基苯甲酰胺的多晶型的方法
RU2792728C2 (ru) СПОСОБ ПОЛУЧЕНИЯ ПОЛИМОРФНОЙ ФОРМЫ 3-[5-АМИНО-4-(3-ЦИАНОБЕНЗОИЛ)ПИРАЗОЛ-1-ил]-N-ЦИКЛОПРОПИЛ-4-МЕТИЛБЕНЗАМИДА
CN120795002A (zh) Axl激酶抑制剂新晶型
TW201636346A (zh) 二－匹多莫德苄乙二胺及其固體型
TW202547456A (zh) Bmx之晶型及其製備方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220310

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251226